위험물

A manufacturing defect occurs when a specific batch or unit of a drug deviates from its intended formula during production, making it more potent, contaminated, or chemically altered in a way that injures the patient.

A design defect exists in every unit of the drug as manufactured, meaning the medication was inherently dangerous even when made exactly as planned. Courts apply either the consumer expectation test or the risk-utility test, the latter of which weighs the drug's benefits against its foreseeable risks and is the more commonly applied standard in pharmaceutical litigation.

A failure-to-warn claim arises when a manufacturer knows or should know of a serious risk but fails to communicate it adequately to prescribing physicians or patients. Each theory requires different evidence and carries different legal burdens, making early legal assessment critical.

Under the learned intermediary doctrine, applied in most U.S. .urisdictions, a drug manufacturer discharges its duty to warn by providing adequate warnings to the prescribing physician rather than directly to the patient.

Direct-to-consumer advertising, over-the-counter drugs, and unusual prescribing circumstances may limit or complicate the learned intermediary defense, depending on state law. The FDA's labeling requirements set a minimum floor, but satisfying federal labeling standards does not automatically bar a state-law failure-to-warn claim.

Because defective drug claims are usually brought under state product liability law, the statute of limitations, punitive damages standard, wrongful death beneficiaries, and scope of the learned intermediary doctrine may differ depending on where the patient lived, received treatment, or filed suit.

FDA approval does not automatically preempt state tort claims against brand-name drug manufacturers. The Supreme Court's decision in Wyeth v. Levine (2009) confirmed that a brand-name manufacturer can be sued under state failure-to-warn law even when FDA-approved labeling was in place, because the manufacturer retains an independent duty to update its warnings when it learns of new safety information.

This ruling means that patients harmed by brand-name medications may have viable claims even when the drug passed every regulatory review. The key question is whether the manufacturer knew or should have known of the risk and failed to act on that knowledge before the patient was harmed.

Claims involving generic drugs are more limited. In PLIVA, Inc. .. Mensing (2011), the Supreme Court held that federal law generally prevents generic manufacturers from independently changing their labels, which preempts most state-law failure-to-warn claims against generic makers.

The Supreme Court extended this reasoning in Mutual Pharmaceutical Co. .. Bartlett (2013), further limiting design defect claims against generic manufacturers where the alleged defect stems from the drug's federally approved composition. Claims involving generic drugs require careful analysis of whether any non-preempted theory, such as a true manufacturing defect or a separate negligence theory, remains available under the facts and applicable jurisdiction. Patients harmed by generic drugs should not assume their claims are automatically barred without consulting a qualified attorney.

Dangerous drug victims may recover compensatory damages covering past and future medical expenses, lost wages, diminished earning capacity, pain and suffering, and loss of enjoyment of life. Where a manufacturer concealed known risks, courts in many jurisdictions also award punitive damages.

Families who lose a loved one due to a dangerous drug may pursue a separate wrongful death claim seeking compensation for funeral expenses, loss of financial support, and loss of companionship. Applicable wrongful death statutes, eligible claimants, and damage caps vary by state.

Adverse drug events remain a major public health concern. According to the FDA's Adverse Event Reporting System (FAERS), the agency receives and analyzes millions of adverse event, medication error, and product quality reports annually, though those reports do not by themselves establish causation in a legal claim. Patients in New York, Washington, D.C., and other jurisdictions should confirm local filing deadlines and product liability standards, as these vary significantly from state to state.

Statutes of limitations for dangerous drug claims typically range from two to four years from the date of injury or discovery, but the exact deadline depends on the state and the specific cause of action.

Most states apply a discovery rule in dangerous drug cases, meaning the statute of limitations begins to run when the plaintiff knew or reasonably should have known that the drug caused the injury, not necessarily when the injury first occurred.

This rule is especially significant in dangerous drug litigation because patients often experience harm months or years after beginning a medication, and the link between the drug and the injury may not become clear until a physician investigation, a public safety alert, or an attorney evaluation. However, discovery rule protections are not unlimited: courts will examine whether a reasonably diligent patient would have investigated the cause of harm earlier.

Patients in any jurisdiction should consult an attorney promptly, because some states impose hard outer limits regardless of discovery, and missing a filing deadline can permanently foreclose otherwise viable claims. An attorney familiar with mass tort litigation can evaluate the timeline and identify which claims remain open.

Most dangerous drug cases proceed as MDL rather than class actions because individual plaintiffs' injuries, medical histories, and damages differ significantly. In an MDL, plaintiffs benefit from shared discovery, reduced litigation costs, and coordinated expert witnesses, while retaining individual control over their claims and settlement decisions.

Bellwether trials in MDL proceedings test representative cases before the full court, and their outcomes typically shape global settlement negotiations for all remaining plaintiffs.

Plaintiffs whose injuries are unusually severe, whose medical histories diverge significantly from the typical MDL claimant, or who have claims under state-law theories not addressed in federal MDL proceedings may achieve better results through individual negotiation or separate state court filings.

A lawyer can evaluate whether an individual lawsuit, MDL claim, or coordinated state proceeding fits the facts of your specific case. Cases involving toxic exposure alongside drug injury may involve overlapping liability theories that benefit from separate handling.

In litigation, a dangerous drug is a prescription or over-the-counter medication that caused injury because of a manufacturing defect, a defective design, inadequate warnings, contamination, or a safety risk the manufacturer failed to disclose. The term does not refer to illegal or controlled substances. Legal claims focus on what the manufacturer knew, what it disclosed, and whether the drug was made and labeled as required.

Yes, in most cases involving brand-name drugs. The Supreme Court held in Wyeth v. Levine (2009) that FDA approval does not automatically preempt state-law failure-to-warn claims against brand-name manufacturers. The analysis is more limited for generic drugs following PLIVA v. Mensing (2011) and Mutual Pharmaceutical v. Bartlett (2013), and available theories vary by jurisdiction.

Preserve the medication and its packaging, keep the warning label and insert, request pharmacy records, document your symptoms and timeline, and speak with both a physician and an attorney before evidence is lost. Do not stop taking a prescribed medication without medical supervision, even if you suspect it is causing harm.

No. An adverse event report can support investigation and help establish that safety signals existed, but it does not prove causation on its own. Medical records, expert testimony, drug labeling history, and analysis of alternative causes are typically required to support a legal claim.

Statutes of limitations typically range from two to four years, but the exact period varies by state and cause of action. Many states apply a discovery rule that starts the clock when the patient knew or reasonably should have known that the drug caused the harm. Some states also impose maximum outer limits regardless of discovery. Consulting an attorney promptly is the only way to confirm whether your claim is still timely.

A class action consolidates plaintiffs with nearly identical claims into one case with shared damages. An MDL consolidates federal cases with common facts for pretrial purposes but preserves each plaintiff's individual claim and damages. Most dangerous drug cases proceed through MDL because injuries and medical histories differ too significantly for class treatment.

Yes. Surviving family members may bring a wrongful death claim seeking compensation for funeral costs, loss of financial support, and loss of companionship. Some states also permit survival claims that allow the estate to recover for the decedent's pain and suffering before death. Eligible claimants and applicable damages vary by state.